{"id":"NCT03806790","sponsor":"LEO Pharma","briefTitle":"Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris","officialTitle":"Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-24","primaryCompletion":"2019-06-10","completion":"2019-06-10","firstPosted":"2019-01-16","resultsPosted":"2020-12-16","lastUpdate":"2025-03-10"},"enrollment":182,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis Vulgaris"],"interventions":[{"type":"DRUG","name":"LEO 90100 foam","otherNames":["Enstilar® Foam"]},{"type":"DRUG","name":"Dovobet® ointment","otherNames":[]}],"arms":[{"label":"LEO 90100 foam","type":"EXPERIMENTAL"},{"label":"Dovobet® ointment","type":"ACTIVE_COMPARATOR"}],"summary":"Comparison of the efficacy of LEO 90100 foam with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.","primaryOutcome":{"measure":"Overall Improvement Rate for the Target Lesion","timeFrame":"End of Week 4","effectByArm":[{"arm":"LEO 90100 Foam","deltaMin":86,"sd":null},{"arm":"Dovobet® Ointment","deltaMin":89,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.120"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":87},"commonTop":["Nasopharyngitis","Acne","Arthralgia","Arthritis","Tendonitis"]}}